An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart® 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart® 0.5mg and Omnic® 0.4mg Commercial Capsules in Healthy Male Subjects.

Brief Summary

Detailed Description

The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia. The design of the present study relies on data obtained in pivotal bioequivalence study and Russian guidance on high quality bioequivalence studies. Summary of treatment groups Treatment Sequence Number of subjects 1. 18 2. 18 Total number of subjects 36 Eligible subjects will be admitted to the research unit one day prior to dosing (Day 0) and will remain as inpatients until approximately 72 hours after dosing. Subjects will undergo a washout period of approximately 28 days from each dose of study medication. During washout period subjects will be contacted via telephone within approximately 10-14 days after the dosing for the collection of information about adverse events and medications taken by volunteers during washout period Overall study duration could be about 2 months - Screening up to 21 days + 10 days (5 days of each of 2 treatment periods) + 28 days washout period between treatment administration + 10-14 days of follow up period. Upon completion of the last dosing session, subjects will be contacted via telephone within approximately 10-14 days for a follow-up inquiry (or visit at the discretion of the investigator) and will be subsequently discharged from the study. * Order of Assessments and Procedures Where multiple measurements/evaluations are scheduled for the same time then the measurements/evaluations will be taken in the following order: 1. Vital Signs 2. Orthostatic Vital Signs 3. PK - Blood Sample Where multiple measurements/evaluations are scheduled for the same time then the study co-coordinator will attempt to ensure that the PK samples are drawn as close to the scheduled time as possible whilst adhering to the order of assessments as described above. * Blinding and Randomisation On Day 0 of the first treatment period, subjects will be randomly allocated at the ratio of 1:1 to one of 2 treatments (refer to Table 1), according to a computer-generated randomisation list. CRO will generate the randomisation list. For the purpose of randomisation screening numbers of volunteers will be used; randomisation numbers will not be assigned to study subjects. Treatment will be open-label; therefore, blinding procedures are not applicable. * Number of Subjects Approximately 50 healthy male subjects will be screened to allow 36 eligible subjects to be randomized and ensure that 30 subjects complete the study according to the protocol without violations. * PHARMACOKINETIC PARAMETERS * Drug assay Dutasteride and tamsulosin will be extracted from human plasma by liquid-liquid extraction using organic solvent. Extracts will be analysed by validated high-performance liquid chromatography - mass spectrometry. The lower limit of detection is about 0.1ng/mL * Calculation of Pharmacokinetic Parameters Pharmacokinetic parameters will be computed for each subject and treatment using standard methods as described in Appendix II. For tamsulosin, the following PK parameters will be computed: * Cmax * Tmax * AUC(0-t) * AUC(0-∞) * Half-life * Mean residence time For dutasteride, the following PK parameters will be computed: * Cmax * Tmax * AUC(0-t) * Mean residence time The half-life and AUC(0-∞) will be computed only for tamsulosin because duration of sampling period equal to 72 h is expected to be non-sufficient for reliable computation of half-life and AUC(0-∞) of dutasteride given the complex pharmacokinetics of dutasteride and long half-life of dutasteride at each of two elimination pathways \[12\]. * ADVERSE EVENTS (AE) AND SERIOUS ADVERSE EVENTS (SAE) The investigator or site staff is responsible for detecting, documenting and reporting events that meet the definition of an AE or SAE. AEs will be collected from the start of Study Treatment and until the follow-up contact. SAEs will be collected over the same time period as stated above for AEs. However, any SAEs assessed as related to study participation (e.g. study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product will be recorded from the time a subject consents to participate in the study up to and including any follow-up contact. All SAEs will be recorded and reported to GSK within 24 hours * LIFESTYLE AND/OR DIETARY RESTRICTIONS * Meals and meal composition Subjects will be required to fast for approximately 10 hours prior to dosing, with the exception of water, which will be allowed freely except for 1 hour before and 1 hour after dosing. Following dosing, subjects will not be allowed food until 4 hours post dose. Meals will be served at the times outlined in Section 2 (Schedule of Assessments), in a seated position (unless orthostasis detected, in which meals should be served in a semi-recumbent position). Meals will be served on Days 2 and 3 at approximately the same time as on Day 1. Subjects will not be allowed to consume the following foods or drinks within 7 days prior to the first dose of study medication until after collection of the final pharmacokinetic blood sample: grapefruit juice; red wine; grapefruit or cruciferous vegetables (watercress, broccoli, cabbage, Brussels sprouts). * Dosage and Administration One Duodart® 0.5mg/0.4mg capsule as Test formulation or one Avodart® 0.5 mg and one Omnic® 0.4 mg capsules as Reference formulation will be administered in the morning of Day 1 in each study period. The capsules should not be opened or chewed, but swallowed whole with 200 mL of water at room temperature * STATISTICAL METHODS * Population for analysis For pharmacokinetics parameters calculation and statistical analysis, the data received from no less than 30 volunteers who have completed the study according to the Protocol will be explored. Safety analysis population of this study will consist of all volunteers who took part in at least one study stage. Data from volunteers who discontinued the study prematurely will be included in the final report, but no included in the pharmacokinetics parameters calculation and statistical analysis. If the volunteer has not taken any of the study drugs at all, his/her data are not to be included in the statistical analysis. * Analysis Method For pharmacokinetics parameters calculation, statistical analysis, and results presentation statistical packages (Statistics, Microsoft Excel 2007, SAS, or SPSS) will be used. Descriptive statistics will be used to present the mean value, standard deviation, median value, minimal and maximal value. Analysis of variance will be done based on the assumption about the log-normal distribution of AUC, Cmax, and Cmax/AUC, and normal distribution of other pharmacokinetics parameters except tmax. The comparison of average values of the investigated and comparator drug parameters is performed with the multiplicative model as a basis and confidence intervals built for the ratio of the corresponding mean values. After the logarithmic transformation these values will be analyzed by analysis of variance (ANOVA).

Primary Outcomes

Secondary Outcomes

• to evaluate the safety and tolerability of the Combination Capsule formulation of dutasteride 0.5 mg/ tamsulosin HCl 0.4 mg(2 months)